Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.33 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.33 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.33 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38298 | 0.83 | — | — | |
| SCHEMBL6274268 | 0.81 | — | — | |
| SCHEMBL1186594 | 0.79 | — | — | |
| SCHEMBL1477900 | 0.77 | FBP1 (0.39) | CES2CES1DAOFBP1ATM | |
| Ethylene Glycol SCHEMBL27657993 | 0.75 | MEN1 (0.34) | CES2CES1DAOFBP1ATM | |
| Magnesium Chloride Anhydrous SCHEMBL20694921 | 0.75 | TSHR (0.37) | CES2CES1DAOFBP1ATM | |
| SCHEMBL12266209 | 0.74 | LPL (0.50) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL13476017 | 0.74 | ENPP2 (0.50) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL1187403 | 0.74 | RAB9A (0.37) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL24426695 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583888-B2 | Bi-specific extracellular matrix binding peptides and methods of use thereof | UNIVERSITY OF TARTU (EE) | 2026-03-24 | — | — | US | disclosed |
| US-20260048133-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250361270-A1 | TARGETED DELIVERY SYSTEM AND METHODS OF USE THEREFOR | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2025-11-27 | — | — | US | disclosed |
| US-12290569-B2 | Methods and compositions using peptides and proteins with c-terminal elements | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-05-06 | — | — | US | disclosed |
| US-12195558-B2 | Targeted delivery system and methods of use therefor | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240391953-A1 | TUMOR ASSOCIATED MONOCYTE/MACROPHAGE BINDING PEPTIDE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2024-11-28 | — | — | US | disclosed |
| US-11981752-B2 | Tumor associated monocyte/macrophage binding peptide and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240150397-A1 | TARGETED DELIVERY SYSTEM AND METHODS OF USE THEREFOR | Sanford Burnham Prebys Medical Discovery Institute | 2024-05-09 | — | — | US | disclosed |
| US-11512110-B2 | Targeted delivery system and methods of use therefor | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-11-29 | — | — | US | disclosed |
| US-20220175941-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2022-06-09 | — | — | US | disclosed |
| US-20080293675-A1 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | ANACOR PHARMACEUTCALS INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-7390806-B2 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1765359-A2 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | Anacor Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1638578-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | Anacor Pharmaceuticals, Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2006007384-A2 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005013892-A9 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS INC (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050070503-A1 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050054644-A1 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, LLC | 2005-03-10 | — | — | US | disclosed |
| WO-2005013892-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| WO-1997011951-A1 | FUNGICIDES | ZENECA LIMITED (GB) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048133-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | CMKLR2, CRKL, CMKLR1 | CES2 2967/4885CES1 3746/4885DAO 3921/4885 |
| US-20050070503-A1 | Antibiotics containing borinic acid complexes and methods of use | BPGM, BROX, TBCA | CES2 4008/4885CES1 4327/4885DAO 196/4885 |
| US-12583888-B2 | Bi-specific extracellular matrix binding peptides and methods of use thereof | FN1, EDNRB, TNFSF11 | CES2 4831/4885CES1 4590/4885DAO 3328/4885 |
| US-20050054644-A1 | Hydrolytically-resistant boron-containing therapeutics and methods of use | BTD, GAA, GBA3 | CES2 123/4885CES1 256/4885DAO 251/4885 |
| US-20080293675-A1 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | BPGM, BROX, TBCA | CES2 4008/4885CES1 4327/4885DAO 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.